Document is current
Any future updates will be listed below
-
Authors
Williams, Marc J. https://orcid.org/0000-0001-5524-4174
Vázquez-García, Ignacio
Tam, Grittney
Wu, Michelle https://orcid.org/0000-0001-6889-8345
Varice, Nancy https://orcid.org/0009-0008-5813-0808
Havasov, Eliyahu
Shi, Hongyu
Al-Rawi, Duaa H. https://orcid.org/0000-0002-9218-6513
Satas, Gryte
Lees, Hannah J. https://orcid.org/0000-0002-1684-3075
Lee, Jake June-Koo https://orcid.org/0000-0003-1348-4094
Myers, Matthew A. https://orcid.org/0000-0002-9337-5180
Zatzman, Matthew https://orcid.org/0000-0001-5235-4116
Rusk, Nicole https://orcid.org/0000-0003-2663-6288
Ali, Emily https://orcid.org/0009-0004-9372-0679
Shah, Ronak H. https://orcid.org/0000-0001-9042-6213
Berger, Michael F. https://orcid.org/0000-0003-3882-5000
Mohibullah, Neeman
Lakhman, Yulia https://orcid.org/0000-0003-3626-4502
Chi, Dennis S.
Abu-Rustum, Nadeem R.
Aghajanian, Carol
McPherson, Andrew https://orcid.org/0000-0002-5654-5101
Zamarin, Dmitriy https://orcid.org/0000-0002-0094-0161
Loomis, Brian https://orcid.org/0000-0002-1863-1199
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Friedman, Claire F. https://orcid.org/0000-0003-2621-8553
Shah, Sohrab P. https://orcid.org/0000-0001-6402-523X
- License Information
-
More Information
Article History
Received: 21 August 2024
Accepted: 14 August 2025
First Online: 1 October 2025
Competing interests
: B.W. reports grant funding by Repare Therapeutics paid to the institution, outside the submitted work, and employment of a direct family member at AstraZeneca. C.A. reports grants from Clovis, Genentech, AbbVie and AstraZeneca and personal fees from Tesaro, Eisai/Merck, Mersana Therapeutics, Roche/Genentech, AbbVie, AstraZeneca/Merck and Repare Therapeutics, outside the scope of the submitted work. C.A. reports clinical trial funding to the institution from AbbVie, AstraZeneca and Genentech/Roche; participation on a data safety monitoring board or advisory board in AstraZeneca and Merck; unpaid membership of the GOG Foundation Board of Directors and the NRG Oncology Board of Directors. M.F.B. reports consulting fees (Eli Lilly, AstraZeneca, Paige.AI), Research Support (Boundless Bio) and Intellectual Property Rights (SOPHiA Genetics). B.L. reports intellectual property rights (SOPHiA Genetics) and licensing royalties (BioLegend/Revvity). C.F. reports research funding to the institution from Merck, AstraZeneca, Genentech/Roche, Bristol Myers Squibb and Daiichi; uncompensated membership of a scientific advisory board for Merck and Genentech; and is a consultant for OncLive, Aptitude Health, Bristol Myers Squibb and Seagen, all outside the scope of this paper. D.S.C. reports membership of the medical advisory board of Verthermia Acquio and Biom’up, is a paid speaker for AstraZeneca, and holds stock of Doximity, Moderna and BioNTech. D.Z. reports institutional grants from Merck, Genentech, AstraZeneca, Plexxikon and Synthekine, and personal fees from AstraZeneca, Xencor, Memgen, Takeda, Astellas, Immunos, Tessa Therapeutics, Miltenyi and Calidi Biotherapeutics. D.Z. own a patent on use of oncolytic Newcastle Disease Virus for cancer therapy. N.R.A.-R. reports grants to the institution from Stryker/Novadaq and GRAIL, outside the submitted work. S.P.S. reports research funding from AstraZeneca and Bristol Myers Squibb, outside the scope of this work. The other authors declare no competing interests.
